Completed PHASE3 INTERVENTIONAL 2-arm NCT05290545

Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

A Comparative Study of Haploidentical Transplantation Supported by Third-party Cord Blood and Haploidentical Transplantation in Hematological Malignancies

Sponsor: Dongguan People's Hospital

Conditions Hematological Malignancies Hematopoietic Stem Cell Transplantation

Interventions BMSCs Cord PBSCs

Updated 4 times since 2022 Last updated: Aug 12, 2024 Started: Feb 15, 2022 Primary completion: Jan 2, 2023 Completion: Mar 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hematological Malignancies and Hematopoietic Stem Cell Transplantation and is currently completed. Dongguan People's Hospital leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE3
Apr 2022 — Jul 2023 [monthly]

Recruiting PHASE3

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dongguan People's Hospital
First Affiliated Hospital of Guangxi Medical University
First People's Hospital of Chenzhou
Hunan Provincial People's Hospital
Nanfang Hospital, Southern Medical University
The First People's Hospital of Guangzhou
The Seventh Affiliated Hospital of Sun Yat-sen University

Data source: Nanfang Hospital, Southern Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China